Serum levels of omentin and visfatin in patients with metabolic syndrome.

IF 2.5 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Archives of Physiology and Biochemistry Pub Date : 2025-04-11 DOI:10.1080/13813455.2025.2486290

Anita Sherly A, Rukmini M S, Anupama Hegde, Arun S, Himani Kotian

{"title":"Serum levels of omentin and visfatin in patients with metabolic syndrome.","authors":"Anita Sherly A, Rukmini M S, Anupama Hegde, Arun S, Himani Kotian","doi":"10.1080/13813455.2025.2486290","DOIUrl":null,"url":null,"abstract":"Introduction: Metabolic Syndrome (MetS) is a global health concern characterised by cardiometabolic risk factors, dysregulated adipokine signalling and inflammation. The study aimed to assess the serum levels of omentin and visfatin in patients with metabolic syndrome.Methods: The 84-subject hospital-based case-control study included 18-55 years, both genders. Anthropometry, medical history, fasting plasma glucose (FPG), lipid profile, and HOMA-IR were collected. Insulin, omentin, and visfatin were measured using ELISA.Results: Omentin and visfatin levels significantly differed between groups (p < 0.05). The median omentin levels were 50.74 and 45.25; visfatin levels were 0.064 and 0.001, respectively. Omentin correlated with waist circumference, blood pressure, and FPG in controls, while visfatin correlated with HDL and BMI among cases (p < 0.05). Omentin and visfatin were elevated in cases. However, no significant correlation between omentin and visfatin with lipid parameters could be established.Conclusion: Omentin and visfatin levels varied significantly between metabolic syndrome and controls; their correlation with MetS criteria was not significant.","PeriodicalId":8331,"journal":{"name":"Archives of Physiology and Biochemistry","volume":" ","pages":"1-8"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Physiology and Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13813455.2025.2486290","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Metabolic Syndrome (MetS) is a global health concern characterised by cardiometabolic risk factors, dysregulated adipokine signalling and inflammation. The study aimed to assess the serum levels of omentin and visfatin in patients with metabolic syndrome.

Methods: The 84-subject hospital-based case-control study included 18-55 years, both genders. Anthropometry, medical history, fasting plasma glucose (FPG), lipid profile, and HOMA-IR were collected. Insulin, omentin, and visfatin were measured using ELISA.

Results: Omentin and visfatin levels significantly differed between groups (p < 0.05). The median omentin levels were 50.74 and 45.25; visfatin levels were 0.064 and 0.001, respectively. Omentin correlated with waist circumference, blood pressure, and FPG in controls, while visfatin correlated with HDL and BMI among cases (p < 0.05). Omentin and visfatin were elevated in cases. However, no significant correlation between omentin and visfatin with lipid parameters could be established.

Conclusion: Omentin and visfatin levels varied significantly between metabolic syndrome and controls; their correlation with MetS criteria was not significant.

查看原文本刊更多论文

代谢综合征患者血清大网膜蛋白和内脏脂肪素水平。

代谢综合征（MetS）是一种全球性的健康问题，其特征是心脏代谢危险因素、脂肪因子信号传导失调和炎症。该研究旨在评估代谢综合征患者血清中网膜蛋白和内脏素的水平。方法：84例以医院为基础的病例对照研究包括18-55岁的男女。收集人体测量、病史、空腹血糖（FPG）、血脂和HOMA-IR。采用ELISA法测定胰岛素、网膜蛋白和内脏脂肪素。结果：代谢综合征组间Omentin和visfatin水平差异显著（p p）结论：代谢综合征组间Omentin和visfatin水平差异显著；与MetS标准的相关性不显著。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Physiology and Biochemistry ENDOCRINOLOGY & METABOLISM-PHYSIOLOGY

CiteScore

6.90

自引率

3.30%

发文量

期刊介绍： Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders. The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications. Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics: -Dysregulation of hormone receptors and signal transduction -Contribution of gene variants and gene regulatory processes -Impairment of intermediary metabolism at the cellular level -Secretion and metabolism of peptides and other factors that mediate cellular crosstalk -Therapeutic strategies for managing metabolic diseases Special issues dedicated to topics in the field will be published regularly.